dnazymes การใช้

• Additionally, SELEX has been utilized to obtain highly specific catalytic DNA or DNAzymes.
• Almost all DNAzymes require metal ions for their function; thus they are classified as metalloenzymes.
• Deoxyribozymes, also called DNAzymes or catalytic DNA, are first discovered in 1994 and quickly emerged as a new class of metalloenzymes.
• Although ribozymes mostly catalyze cleavage of RNA substrates, variety of reactions can be catalyzed by DNAzymes including RNA / DNA cleavage, RNA / DNA ligation, amino acid phosphorylation and dephosphorylation, and carbon carbon bond formation.
• Yet, DNAzymes that catalyze RNA cleavage reaction are the most extensively explored ones . 10-23 DNAzyme, discovered in 1997, is one of the most studied catalytic DNAs with clinical applications as a therapeutic agent.
• Several metal-specific DNAzymes have been reported including the GR-5 DNAzyme ( lead-specific ), the CA1-3 DNAzymes ( copper-specific ), the 39E DNAzyme ( uranyl-specific ) and the NaA43 DNAzyme ( sodium-specific ).
• Several metal-specific DNAzymes have been reported including the GR-5 DNAzyme ( lead-specific ), the CA1-3 DNAzymes ( copper-specific ), the 39E DNAzyme ( uranyl-specific ) and the NaA43 DNAzyme ( sodium-specific ).
• The outcome of two other clinical trials evaluating DNAzymes performed in Asia and Europe were reported in 2014 and 2015, the former assessing a Epstein Barr virus latent membrane protein 1 targeting DNAzyme and the latter a DNAzyme targeting the transcription factor GATA3 which involved 7 trial sites.
• This was later followed by numerous other independent, some multi-center, clinical trials evaluating DNAzymes in humans, including DNAzymes targeting EBV-LMP1 in patients with nasopharyngeal cancer and DNAzymes targeting another nuclear transcription factor GATA3 in patients with allergic asthma demonstrating DNAzyme efficacy and safety.
• This was later followed by numerous other independent, some multi-center, clinical trials evaluating DNAzymes in humans, including DNAzymes targeting EBV-LMP1 in patients with nasopharyngeal cancer and DNAzymes targeting another nuclear transcription factor GATA3 in patients with allergic asthma demonstrating DNAzyme efficacy and safety.
• This was later followed by numerous other independent, some multi-center, clinical trials evaluating DNAzymes in humans, including DNAzymes targeting EBV-LMP1 in patients with nasopharyngeal cancer and DNAzymes targeting another nuclear transcription factor GATA3 in patients with allergic asthma demonstrating DNAzyme efficacy and safety.